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Liberalization, Firm Size and R&D performance:  
A Firm Level Study of Indian Pharmaceutical Industry 
_______________________________________________________________________ 
Abstract: In the present paper, it is attempted to empirically verif y the impact of 
economic liberalization on the R&D behaviour of Indian pharmaceutical firms 
controlling for the effects of several firm specific characteristics including firm size. The 
results from the Tobit analysis for a sample of firms over the period 1989-90 to 2000-01 
indicate that competitive pressure generated by liberalization has worked effectively in 
pushing Indian pharmaceutical firms into R&D activity. A host of firm characteristics 
like firm age, size, profitability, intangible assets, export orientation and outward foreign 
direct investment are also found to be important determinants of innovative activity in 
the industry. The study suggests several policy measures to further indigenous 
technological efforts of pharmaceutical firms, which include, removing obstacles that 
inhibit outward orientation of firms, providing special scheme for small size firms in the 
overall technology policy for the industry, intensifying collaborative research efforts 
between private sectors and government research institution, and utilizing flexibilities in 
the TRIMs agreements to persuade foreign firms to relocate their R&D units into the 
country. 
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I. Introduction 
 
India’s pharmaceutical industry today stands among the technologically most 
vibrant segments of Indian manufacturing. It is well understood in the literature that the 
level of growth and technological development exhibited by the industry is a success of 
strategic policy interventions consciously undertaken since late 1960s with the specific 
objectives of self-sufficiency in drugs production, self-reliance in drugs technology and 
accessibility of quality drugs at reasonable prices1. These interventions included 
encouraging indigenous production and technological developments through local 
content and linkage requirements, incentives to local R&D, encouraging generics over 
branded products, subsidizing small-scale sectors, Drug Prices Control Order (DPCO) 
                                                             
1 See Kumar and Pradhan (2002) for details of policy changes and its impact on the growth of Indian 
pharmaceutical industry. 
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and containing the activities of foreign multinational enterprises (MNEs) through 
Foreign Exchange Regulation Act (FERA) and discriminatory licensing system. The soft 
Intellectual Property Protection (IPR) regime as envisaged in the Patent Act 1970 was a 
turning point in the growth of indigenous pharmaceutical industry. The provisions of 
process patents with a maximum duration of patenting reduced to seven years and the 
compulsory licensing after three years from the grant of the patent had boosted local 
innovation, mainly in process and formulation development2. The availability of life 
saving and other drugs in India at a fraction of prices prevailing internationally and 
significantly at a lower time gap between its introduction in the domestic market and 
introduction in the world market underscore the success of favorable policy 
interventions3. At the dawn of Independence, the industry hardly had any technological 
base to start local production and was only processing imported bulk drugs into 
formulations.  By the eighties the industry had accumulated technological capability to 
produce bulk drugs from as basic stage as possible and achieved a high degree of self-
sufficiency concerning its requirements of basic raw materials and intermediates. This 
rising domestic technological capability in the industry is also reflected in the favorable 
trade balance that the country is enjoying in pharmaceutical products since late eighties 
as compared to huge deficits of sixties and seventies.     
However, as a part of the ongoing economic reforms many of the favorable 
policies that had nurtured this industry through decades after Independence are radically 
changing. TRIPs agreements seek to completely undermine the existing process patent 
regime-the heart of growth impetus of the industry. The country has a 10-year transition 
period to implement a 20 years patent protection for an innovation, irrespective of the 
fact that the product is locally manufactured or imported. With the amendments of Indian 
Patent Act, 1970 in December 1999 in Parliament, the mechanism of exclusive 
marketing rights (EMRs) and a mailbox system of accepting product patent are already 
in place as transitory measures to shift to the product patent regime. As per rule, Indian 
companies will not be able to reverse engineer any patented product in the post 2005 
scenario. Even though they have the freedom to do so in the case of all molecules 
                                                             
2 Fikkert (1993), Haksar (1995) and Kumar and Saqib (1996) have argued in their quantitative explorations 
into the R&D activity of Indian firms that the innovative activity of these enterprises has been stimulated 
by the soft patent regime under the 1970 Patent Act. 
3 For example the prices of Ranitidine, Famotidine, Astemizole, Ondansetron in the US market are at about 
50 times the Indian prices and most of these drugs had been introduced in the domestic market within 4-5 
years of their introduction in the world market (see Table-2 in Kumar and Pradhan, 2002)).  
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registered until December 1994, their scope for adaptations and process developments 
will progressively reduce in the long run. Therefore this emerging policy regime has 
significant implications for the future technological developments in the industry. 
The pharmaceutical industry is a research and development intensive industry. 
Therefore, a continuous flow of R&D efforts is essential for the development of 
pharmaceutical industry. In the backdrop of the recent policy reforms, the most 
important question therefore is how has the indigenous technological activity of the 
industry been affected by the new policy regime. The primary objective of the present 
study is to empirically examine the impact of liberalization on the innovative activity in 
Indian pharmaceutical industry. It will also analyze the role of several firm-specific 
characteristics like firm size, age, knowledge acquisition from abroad, export orientation, 
outward investment, multinational affiliations etc which literature on R&D had identified 
as important determinants of R&D behaviour at the firm level. The main purpose of such 
a quantitative analysis is to derive some strategic policy options that can help to 
strengthen the technological life-blood of the industry to maintain its competitiveness in 
a liberalizing regime coupled with product patent system. 
The paper is structured as follows. Section II presents recent trends and patterns 
of R&D in Indian pharmaceutical industry.  Section III formulates the empirical 
framework and hypotheses on the determinants of R&D activity. It also discusses 
methodological issues. The empirical results and discussion are presented in Section IV. 
Section V provides concluding remarks with underlying policy implications.  
 
II. R&D activity in Indian Pharmaceutical Industry: Recent trends and patterns 
 
R&D activity in Indian pharmaceutical industry has increased substantially in the 
latter half of the nineties, both in absolute amount of rupees spent and as a proportion of 
total turnover. The estimated R&D expenditure by the sample firms has risen from mere 
Rs. 8 crores in 1990 to an impressive figure of Rs. 515 crore in 2001 (Table-1).  The 
trend in R&D intensity indicate that the sample firms have spend around 2.2 percent of 
sales in 2001 as compared to 0.2 percent in 1990. In terms of R&D intensity the 
performance of foreign firms is however observed to be contrary to the expectation when 
compared to domestic firms. The observed R&D intensity of domestic firms, 2.6 percent, 
is three and half times higher than that of foreign firms, which is low at 0.74 percent. The 
R&D intensity curve of domestic firms is continuously lying above the sample average 
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since 1994 and has been more or less rising (Figure-1). While that of foreign firms is 
continually lying below sample average after 1994 and appear to be declining since 
1997.  
The advocates of strict patent regime generally argued that product patent would 
lead to an increase in the international technology transfer to India by encouraging 
foreign firms to introduce their new products and relocating their R&D units into the 
country because of its cheap personnel costs. The trends in R&D intensity however 
appear to be not supportive of this view. Foreign firms, given their captive access to the 
laboratories of their parents, are incurring minimal R&D expenditure in the nature of 
local adaptation of their product in the country. This is in accordance with the trend in 
R&D activity of MNEs to be concentrated in the home country because of the economies 
of scale in innovative activities, agglomeration economies, and a need to protect firm-
specific technology. The country had bitter experience of the Patent and Designs Act, 
1911 where strong patent regime led foreign firms to be merely engaging in trading 
activities by processing imported bulk drugs into formulations and virtually holding back 
indigenous efforts towards technological self sufficiency4.  Empirical studies on the 
relationship between patent protection and location of R&D activity by MNCs fails to 
detect any significant correlation in the case of developing countries5. Therefore, the low 
R&D intensity of foreign firms as compared to domestic firms should not surprise us. 
Nor should we expect that their R&D intensity is going to be changed substantially after 
the product patent regime come into force. Given their monopoly status enjoyed under 
TRIPs and also the provision that imports of the product is akin to local production the 
hope on foreign firms as a source of R&D activity may be unrealistic. 
 
 
 
 
                                                             
4 Desai (1980) documented two cases where foreign patent owner neither had used their patents for 
domestic manufacturing nor allowing them to be used by local firms. These are: (1) Hoeshst preventing 
Unichem Laboratories from producing tolbutamide and (2) Thereupon Excel Industries being prevented 
from producing the fumigant by another foreign firm.    
5 Kumar (1996) found that R&D intensity of US affiliates is positively and significantly dependent upon 
the strength of patent protection (Rapp and Rozek index) in the case of developed countries but not 
statistically different from zero for developing countries. Kumar (2001) in a more recent study confirmed 
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Table-1 R&D intensity in Indian Pharmaceutical Industry, 1990-2001 
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1990 61 4 6.6 8 0.20 45 2 4.4 3 0.12 16 2 12.5 5 0.30 
1991 82 6 7.3 5 0.11 65 4 6.2 1 0.02 17 2 11.8 5 0.25 
1992 101 21 20.8 13 0.21 84 16 19.0 7 0.18 17 5 29.4 6 0.26 
1993 124 47 37.9 57 0.77 106 33 31.1 35 0.74 18 14 77.8 22 0.84 
1994 175 62 35.4 113 1.23 157 50 31.8 90 1.49 18 12 66.7 23 0.73 
1995 215 79 36.7 174 1.48 197 64 32.5 149 1.80 18 15 83.3 25 0.72 
1996 234 90 38.5 192 1.38 215 74 34.4 162 1.55 19 16 84.2 30 0.88 
1997 221 94 42.5 260 1.59 202 78 38.6 224 1.80 19 16 84.2 36 0.91 
1998 220 85 38.6 248 1.39 201 69 34.3 210 1.57 19 16 84.2 38 0.86 
1999 221 82 37.1 298 1.50 200 67 33.5 264 1.75 21 15 71.4 35 0.71 
2000 229 84 36.7 340 1.55 208 71 34.1 305 1.83 21 13 61.9 34 0.65 
2001 188 77 41.0 515 2.21 171 64 37.4 479 2.60 17 13 76.5 36 0.74 
Note: Data are for fiscal year ending March 31 of the year shown 
Source: Authors’ computation based on RIS-DSIR database (2002)  
 
 
 
Figure-1: R&D in Indian Pharmaceutical Industry, 1990-2001 
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Note: Bars represent R&D expenditure; lines represent R&D intensity.  
 
                                                                                                                                                                                   
that the strength of patent protection (Ginarte and Park index) is not a significant factor in explaining R&D 
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Even though it is encouraging to find that R&D intensity of the industry has risen 
substantially in the latter part of the nineties, it is very low compared to existing 
international level of 10-15 percent of sales.  The fact that there are only one-thirds of 
sample firms incurring R&D expenses in the industry need attention. Further, most of the 
research efforts are confined to the process improvements and to a limited extent 
research on drug delivery system. Barring few firms the industry has not yet made 
progress in channeling research activity into basic research wherein the goal is to invent 
new drugs. The resource constraints appear to explain this inability of private sector 
firms to meet the huge cost entailed in developing a new drug.  This is clear from the fact 
that from Independence to 2001, only 14 new drugs have been developed in the country 
and out of which 11 have come from CSIR, a public funded research institution6. 
  Table-2 gives the distribution of firms over different size classification of R&D 
intensity in 1999-2000 (also see figure-2). The number of firms is unevenly distributed 
across different classes with a strong concentration in the lower end. There are 139 firms 
in the industry who do not undertake any R&D activity (0.0-0.0 size) and another 47 
firms who engage in R&D but amount to less than 1 percent of their total sales (0.0-1.0 
size). Only in case of 16 firms the observed R&D intensity is found to be a respectable 
intensity of 3 percent and above. Therefore, the pattern of R&D activity in Indian 
pharmaceutical industry reveals that majority of firms do not engage in innovative 
activities and majority of those engage spent marginally as proportion of their sales. 
 
 
 Table-2: Distribution of firms according to R&D intensity, 1999-2000 
 R&D intensity (%) Number of firms Percent Cumulative Percent 
0.0-0.0 139 62.3 62.3 
0.0-1.0 47 21.1 83.4 
1.0-3.0 21 9.4 92.8 
3.0-5.0 9 4.0 96.9 
5.0 - above 7 3.1 100.0 
Source: Authors’ computation based on RIS-DSIR database (2002) 
 
 
 
                                                                                                                                                                                   
intensity of US and Japanese affiliates.  
6 GOI, 2001, pp.140  
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Figure-2 Distribution of Firms based on R&D intensity in Indian Pharmaceutical 
Industry, 1999-2000  
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A list of twenty firms with largest R&D expenses incurred during the period 
1999-2000 has been provided in Table-3. Ranbaxy Laboratories Ltd. has spent around 
Rs. 55 crore in R&D activity and tops the rank. It is one of the few research based 
international pharmaceutical companies to drive the competitiveness of the industry in 
international market with subsidiaries in more than 20 countries across the globe. The 
company has a strong presence in the anti-infective segment with 12 brands in the top 
250 in the domestic market. The Indian company that has ranked second in terms of 
R&D expenses is Wockhardt Ltd.  which has very strong presence in antibiotics and 
analgesics. Even though the company stood second in absolute amount of R&D it is at 
the top considering R&D expenses in relation to sales. There are only two foreign firms 
namely Novartis India Ltd. and Glaxosmithkline Pharmaceuticals Ltd, which make into 
the list by virtue of their absolute amount of R&D expenditure. It is important to note 
that these two foreign firms, even though has spent substantial amount on R&D in 
absolute sense, it is in fact very nominal in terms of R&D intensity and these two firms 
stood last in the rank series based on R&D intensity. 
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Table-3 List of twenty firms with highest R&D expenses, 1999-2000  
Name of company Ownershi
p 
R&D 
(In Rs. Crores) 
Rank R&D 
intensity 
Rank 
 Ranbaxy Laboratories Ltd.  Domestic 55.39 1 2.93 9 
 Wockhardt Ltd.  Domestic 40.25 2 7.21 1 
 Cipla Ltd.  Domestic 30.02 3 3.89 7 
 Cadila Healthcare Ltd.  Domestic 21.27 4 4.45 4 
 Sun Pharmaceutical Inds. Ltd.  Domestic 18.8 5 3.92 6 
 Aurobindo Pharma Ltd.  Domestic 14.34 6 1.92 11 
 U S V Ltd.  Domestic 14.23 7 5.93 3 
 Pfizer Ltd.  Domestic 13.47 8 4.08 5 
 Dr. Reddy'S Laboratories Ltd.  Domestic 13.27 9 2.69 10 
 Panacea Biotec Ltd.  Domestic 12.59 10 6.48 2 
 Lupin Laboratories Ltd. [Merged]  Domestic 9.32 11 1.71 15 
 Nicholas Piramal India Ltd.  Domestic 9.26 12 1.89 12 
 Novartis India Ltd.  Foreign 6.72 13 0.81 19 
 Ipca Laboratories Ltd.  Domestic 6.44 14 1.75 13.5 
 Glenmark Pharmaceuticals Ltd.  Domestic 5.2 15 3.58 8 
 Orchid Chemicals & Pharmaceuticals Ltd.  Domestic 4.54 16 1.26 18 
 Glaxosmithkline Pharmaceuticals Ltd.  Foreign 4.14 17 0.43 20 
 Unichem Laboratories Ltd.  Domestic 3.62 18 1.75 13.5 
 Cheminor Drugs Ltd. [Merged]  Domestic 3.51 19 1.53 16 
 R P G Life Sciences Ltd.  Domestic 3.1 20 1.47 17 
Source: Authors’ computation based on RIS-DSIR database (2002) 
 
 
 
III. Determinants of R&D behaviour: The Framework and Hypotheses 
 
The R&D behaviour of a firm is generally conceptualized into two important 
decisions that it has to make: (1) whether it will engage in R&D activity or not and if yes 
(2) how much resources it will devote for this purpose. The first question boils down to 
estimating the probability to do R&D and the second one is estimating an R&D intensity 
regression. In this case the obvious choice is to estimate a Tobit model for Indian 
pharmaceutical firms of the following form:   
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Where X it is a vector of k (k=1…k) factors that explain the R&D intensity 
(R&Dit) of ith (i=1…227) firm in tth time (t=1989-90…2000-
coefficients and uit is a normally distributed error term.   
The important reason for estimating a Tobit model is the fact that the dependent 
variable R&D intensity takes on the value of zero for a large proportion of cases and 
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hence simple OLS estimation will produce biased estimate. As there are two types of 
effects associated with each independent variable in the Tobit model – (1) the effects on 
the value of R&D intensity for cases at the limit value (i.e. zero) and (2) another for 
cases above the limit, the single ordinary Tobit coefficient is not directly interpretable. 
Researchers often make mistake by interpreting Tobit coefficients as the effects of 
independent variables on the dependent variable for cases above the limit. McDonald and 
Moffitt’s (1980, P. 318) decomposition is therefore highly useful by the fact that it 
disaggregates Tobit effects into these two types of effects: 
 
)2.1(
)(
)&(
)&(
)(
)&( *
*
÷÷
ø
ö
çç
è
æ
¶
¶
+÷÷
ø
ö
çç
è
æ
¶
¶
=
¶
¶
kkk X
zF
DRE
X
DRE
zF
X
DRE
 
Where F(z) is the cumulative normal distribution function for the proportion of 
cases above the limit. E(R&D) is the expected value of R&D intensity for all cases 
(firms with and without R&D). E(R&D*)  is the expected value of R&D for cases above 
the limit (firms with R&D). E(R&D*)/Xk is the change in the expected value of R&D 
intensity for cases above the limit (with R&D).  F(z)/Xk is the change in the 
cumulative probability of being above the limit (having R&D) associated with an 
independent variable.  
Thus, equation (1.2) states that the total change in R&D consists of two 
interesting effects: (1) the change in R&D intensity of firms incurring R&D, weighted by 
the probability of doing R&D; and (2) the change in the probability of doing R&D, 
weighted by the expected value of R&D of firms if incurring R&D. The study will 
estimate this decomposition for deriving more information than what ordinary Tobit 
coefficient commonly provide. 
Following the earlie r theoretical and empirical literature on the determinants of 
R&D activity at firm-level for India and other countries the study envisage that R&D 
activity of pharmaceutical firms may depend upon a number of factors (X it) as discussed 
below.     
 
 
Firm Size  
 
Most of the empirical literature on the determinants of R&D following the 
Schumpeterian perspective of innovation stresses firm size as an important factor 
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influencing R&D behaviour of firms (for recent surveys see Cohen, 1995; Kumar and 
Siddharthan, 1997). The basic Schumpeterian hypothesis visualizes a direct positive 
relationship between firm size and innovation. Larger the firm size the larger its market 
power and larger its capacity to appropriate economic rent from innovative activity. By 
nature R&D activities involve huge financial resources, contain considerable risks and 
the outcome is unpredictable (Lall, 1992). Firm size, which is considered to proxy for the 
resource base of the firm, risk perception and scale economies, is thus predicted to be 
favorably affecting the R&D behaviour of firms. The empirical findings on the role of 
firm size however is observed to be mixed in the case of Indian manufacturing. Lall 
(1983) for a sample of 100 Indian engineering firms for the year 1978 found that R&D 
intensity of the sample firms depend positively on their size.  For a cross-section of 
industries for the year 1978-79 Katrak (1985) reported a less than proportionate increase 
in R&D expenditure with an increase in firm size. There are another group of studies, 
which detected a non-linear relationship between firm size and R&D behaviour. 
Siddharthan (1988) for a sample of 166 manufacturing firms over the period 1982-85 
found that the relationship between R&D intensity and firm size is U-shaped. The R&D 
intensity of firms decreases until firm size, as measured by sales, reached a threshold 
limit of Rs. 600 million and thereafter it increases with sales volume. Kumar and Saqib 
(1996) have estimated both Probit and Tobit models for a sample of 291 Indian 
manufacturing firms for the period 1977-78 to 1980-81 to examine the determinants of 
probability and intensity of R&D expenditure respectively.  They found an inverted-‘U’ 
shaped relationship between firm size and probability to undertake R&D activity 
whereas the R&D intensity of firms is positively and linearly related to firm size. In a 
recent study, Kumar and Agarwal (2000) for a much larger sample of Indian 
manufacturing firms over the period 1992-93 to 1998-99 have reported a horizontal S-
shaped relationship between firm size and R&D intensity. In the pooled OLS estimation, 
firm size and its cubic term have a significant negative coefficient whereas quadratic 
term has a significant positive coefficient.  In view of the inconclusive findings on the 
role of firm size in innovative activity in Indian manufacturing the present study will also 
examine for possible non-linear relationship. Specifically firm size (SIZE) as well as its 
quadratic term (SIZE2) will be included in the estimation of model (1.1).  
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 Imports of Foreign Technology  
As firms of developing countries tend to have limited research capabilities to 
develop their indigenous technological capabilities, they resort to imports of technologies 
from abroad. A domestic firm can import technological inputs like plant and machinery 
and further it can acquire knowledge through technology and know-how agreements. 
How are these embodied and disembodied channels of technology imports related to own 
in-house R&D activity of the firm? To the extent that imports of foreign technology 
require further R&D on the part of importing entity to absorb, adapt and assimilate the 
imported knowledge to local conditions, it may stimulate local knowledge-creating 
activities. It is also possible that the relationship will be dominated by substitution when 
availability and use of foreign technology discourage and hence substitute R&D activity 
of receiving firms. The nature of R&D determines whether the relationship will be 
complementary or a substituting type. If R&D activity is mainly of an adaptive type as 
assumed by Lall (1983) and Katrak (1985) for R&D activity in Indian manufacturing 
then a complementary relationship can be postulated. Previous studies on Indian 
manufacturing predominantly indicate a complementary relationship between imports of 
foreign technology and R&D activity of domestic firms (Lall, 1983; Katrak, 1985, 1990; 
Kumar, 1987; Siddharthan, 1988; Deolalikar and Evenson, 1989; Basant, 1997; Kumar 
and Agarwal, 2000). To test the impact of foreign technology on local R&D activity of 
Indian pharmaceutical firms, the study has included two variables- DISTECH (royalties 
and technical fee paid abroad by the firm as a percentage of sales) and EMTECH 
(imports of capital goods as a percentage of sales.) as two measures of technology 
imports.  
 
Outward Orientation 
 
R&D performance of firms may also depend upon whether the firm is outward 
oriented or not and if yes the degree and mode of outward orientation. An outward 
oriented firm is one who sees not only domestic market but also external market as an 
important avenue for its growth and expansion. It can serve the external market through 
export or outward direct investment. In a knowledge-intensive segment of global market 
like pharmaceutical, the export competitiveness increasingly lies in consciously created 
firm-specific knowledge like better quality, innovative design and marketing by 
incurring greater R&D expenses. Therefore, the export intensity (EXPOINT) of a firm is 
 13 
expected to affect favorably its R&D activity. Braga and Willmore (1991) for Brazil and 
Kumar and Saqib (1996) and Kumar and Agarwal (2000) for India have found that 
diversification of firms into international markets significantly increases both their 
probability to do R&D and ability to do R&D more out of total sales. When the outward 
oriented firm chooses to serve the external market through the mode of foreign direct 
investment, the industrial organization theory suggests that such international operation 
of firms can be possible only when it possessed some monopolistic advantages 
conferring on it some superiority over local rivals in that market7. The R&D is an 
important channel of accumulating monopolistic advantages and therefore firms aspiring 
to go for international production are likely to undertake R&D activity. Lall (1983) 
documented that the proprietary advantages of Indian firms operating overseas activity 
mainly depend upon their ability to reproduce a given technology, assimilating and 
adapting to local raw materials or operating conditions rather than pushing back the 
frontiers of knowledge. Several other studies on the third-world MNEs (TWMNEs) such 
as on Korean MNEs (Kumar and Kim, 1984; Euh and Min, 1986), on Hong Kong MNEs 
(Chen, 1983), on Argentine MNEs (Katz and Kosacoff, 1983) and on Brazilian MNEs 
(Villela, 1983) suggests that the technological strength of developing countries MNEs 
lies in their ability in local adaptations and modifications and sometimes little 
improvements of imported technologies. Therefore, literature on TWMNEs indicate that 
firms undertaking direct investment abroad from developing countries have strengthened 
their technological capabilities by undertaking R&D mainly in the nature of adaptation, 
assimilation and improvements of foreign technologies. The study thus postulated a 
positive relationship between the variable of outward investment (OINV) and R&D 
performance.   
 
Ownership 
 
In the case of ownership of the firm the working hypothesis is that the foreign 
firms spend relatively lower than what domestic firms spend on R&D. It is argued that 
foreign affiliates tend to do little R&D because they have captive access to the 
                                                             
7 The industrial organization theory of FDI as proposed by Hymer (1960) and later extended by 
Kindleberger (1969) and Caves (1971) has been the most dominant explanation for foreign operation of 
national firms. This approach traces the existence and growth of the international operation of firms in the 
phenomenon of market imperfections. According to Hymer firms undertaking investment abroad must 
possess some monopolistic advantages like product differentiation, management skill, patents and superior 
technology, control of the supply of key raw materials, economies of scale, etc which they can profitably 
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laboratories of their parents situated in home country. This hypothesis has been tested by 
several studies in India (Kumar, 1987; Kumar and Saqib, 1996; Kumar and Agarwal, 
2000) and overwhelming evidence suggests that foreign firms in Indian manufacturing 
have done significantly less R&D than their domestic counterparts. Many studies on the 
internationalization of innovative activities also suggest that MNEs tend to conduct little 
R&D outside their home base (Patel and Pavitt, 1995; Patel and Vega, 1999). Amsden 
(2001) in a study on major developing countries of East Asia and Latin America found 
that more the foreign ownership less is the depth and breadth of R&D. Among 
developing countries Singapore stands out to be an outlier in the sense that MNE 
affiliates had undertaken large proportion of R&D accounting for more than one-third of 
Singapore’s total R&D spending. However even in the case of Singapore it was found 
that the R&D activities conducted by foreign companies are rarely of basic research or 
even applied research and are generally less advanced than at corporate headquarters 
(Amsden et. al. 2001). Therefore, a negative coefficient for the foreign dummy (FDUM) 
has been postulated in the model. 
 
Intangible Assets of Firms 
R&D activity of a firm can be argued to depend positively on the intangible 
assets (INASSET) of the firm. Firms with superior intangible assets in the form of trade 
marks, brands, copy-rights and consumer goodwill are likely to invest more in R&D as 
their brand superiority enable them to better appropriate returns from their innovative 
activity. Brand loyalty gives the firm required monopoly power to undertake R&D and 
meet the preferences of a more informed consumer today.  
 
Firm Age 
Technological capacity building by a firm is an incremental and cumulative 
process, which requires that the firm must accumulate knowledge, skills, learning, 
operating know-how and experience that support continuous changes and improvements 
in production process, products and procedures (Bell and Pavitt, 1992; Aw and Batra, 
1998). A firm learns from past production experiences and use these accumulated 
learning for further technological improvement. Therefore, firm age (AGE) as a proxy 
                                                                                                                                                                                   
exploit abroad by internalizing production rather than exporting from home country or licensing those 
advantages to a third party abroad.     
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for accumulated experience and technological learning is hypothesized to affect R&D 
performance positively.  
 
Profit Margins 
 
Given the fact that R&D activity involves huge resource capability on the part of 
innovating firm, a higher profit margin indicating internal resource generation is likely to 
have favorable impact on R&D decision of the firm (Kumar and Saqib, 1996; Kumar and 
Agarwal, 2000). This variable also captures the impact of fiscal measures like tax 
exemption offered by the government for firms with recognized R&D units. Other things 
being constant it is expected that a higher profit margin (PMRG) is likely to induce firm 
to undertake R&D and spent more as a proportion of sales. 
 
Liberalization 
 
There has been a radical shift in the country’s policy framework governing 
production and trade in 1991. Along with several regulatory changes in the Indian 
economy including abolition of mandatory licensing system and liberalizing FDI policy, 
the hold of price control on pharmaceutical industry has been significantly reduced.   The 
domestic firms no longer can count on domestic markets for their growth and survival. In 
the face of stiffer competition from free imports as well as entry of new foreign firms 
they are forced to utilize their resources and constantly upgrade and improve their 
technological capabilities. To the extent liberalization force firms to undertake R&D on 
account of foreign competition for their survival, a positive relationship between 
Liberalization and R&D can be expected. The effect of liberalization has been captured 
by including a dummy variable (LIBDUM) taking value of 1 for reform period (1993-94 
to 2000-01) and 0 for pre-reform period (1989-90 to 1992-93). 
After discussing about the probable determinants of R&D, now we will include 
them into our model explicitly to obtain the following form: 
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Fitting a regression equation like equation (1.3) for the search of the determinants 
of firms’ R&D behaviour has been the standard practice in the literature. However, 
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regressing R&D expenditure on its supposed determinants in a contemporaneous setting 
as pursued by the majority of existing studies and the present study suffers from the 
problem of simultaneity. The R&D behaviour of firms is a complex phenomenon and the 
lines of causation often run from supposed determinants to R&D and from R&D to its 
supposed determinants. For example, foreign technology purchase by firms may depend 
on their initial indigenous technological capabilities (Katrak, 1997) or high profit 
margins of the firm may itself have resulted from its successful R&D activities (Kumar 
and Saqib, 1996). A few of the previous studies have used lagged independent variables 
in the estimation but precedence in time does not necessarily distinguish causes from 
effects. Although the simultaneous equations approach has not been pursued, the single 
equation Tobit estimation adopted in the study serves as a useful exploratory estimation.  
 
IV. Results and discussions  
 
The model (1.3) has been estimated for a sample of 277 Indian pharmaceutical 
firms over the period 1989-90 to 2000-01. The study draws upon an exclusive RIS-DSIR 
database to conduct the quantitative analysis. Details about the database used and 
measurements of variable has been provided in the appendix A. Table -4 reports the 
maximum likelihood estimation of pooled Tobit model as well as panel data random-
effects Tobit estimation. The pooled estimation results given under the heading column-
A have been provided with robust standard errors. STATA-the statistical package used 
for the estimation purpose produces robust standard errors using the Huber-White 
sandwich estimators which can effectively deal with a collection of minor problems of 
not meeting the classical regression assumptions, namely about normality, 
heteroscedasticity, or some observations that exhibit large residuals, leverage or 
influence.  In column-B we have provided fully standardized coefficients of independent 
variables which are by construction scale free and hence are useful in comparing the 
relative strength of the independent variables in terms of effect on the dependent 
variable. As discussed before the ordinary output as presented under column-A provide 
only one unstandardized Tobit coefficient for each independent variable, notwithstanding 
the presence of two types of cases- those with zero value of R&D intensity (firms not 
incurring R&D) and those with non-zero value of R&D (firms doing R&D). Therefore, 
these single Tobit coefficients are not useful for effective interpretations. We have 
provided two types of marginal effects in McDonald-Moffitt Decomposition framework, 
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which are directly and effectively interpretable (Column-C & D). In view of the panel 
structure of our dataset we also have estimated random-effects Tobit model and results 
obtained thereof has been presented in column-E. As theoretical developments on the 
conditional fixed-effects Tobit model is still in infancy and there does not exist a 
sufficient statistic allowing the fixed effects to be conditioned out of the likelihood, we 
are not able to provide results from fixed effects. However, it is possible to estimate 
unconditional fixed effects model by including firm-specific dummies in the estimation 
but results obtained will be biased and hence inferences drawn on that results will be 
misleading.  
 
The reported Wald Chi-square statistics for pooled and random-effects Tobit 
model indicate that the estimated models are statistically significant. That means taken 
together all our independent variables explain a significant proportion of variation in the 
dependent variable. It is remarkable that the overall conclusions derived from pooled 
Tobit model are same as those provided by the random-effects Tobit model. This 
similarity thus suggests that obtained results on the determinants of R&D activity is 
robust to alternative estimation procedures, at least between the pooled and random-
effects model. The performance of individual independent variables are as discussed 
below. 
 
Age: The role of firm age in the R&D performance of firms in Indian pharmaceutical 
industry is found to be favorable. Both the pooled and random-effects model indicate 
that the variable has a positive coefficient, which is statistically significant at 1 percent 
level. Keeping all else constant, a one-year increase in age, on an average, produces 
about 0.012 increase in R&D intensity of sample firms and about 0.002 increase in their 
probability to undertake R&D activity. This strongly supports our hypothesis that older 
firms in the industry have the competitive advantages of technological learning and 
experience in doing R&D as compared to start-ups. The vector of standardized 
coefficients, however, indicate that the relative contribution of firm age in the 
explanation of R&D behaviour of pharmaceutical firms is less dominant than other 
factors like PMRG, SIZE, INASSET, etc. In particular, for a standard deviation increase 
in age, R&D intensity is expected to increase by 0.117 standard deviations, holding all 
other variables constant.    
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Table-4 Tobit estimation of R&D intensity  
Dependent variable: R&D intensity (%) 
Pooled Tobit Estimation 
McDonald-Moffitt 
Decomposition 
Random-effects 
Tobit 
Estimation 
Marginal Effects at Means 
Coefficients 
(Robust Z-
value) 
Fully 
Standardized 
coefficients 
¶Ey*/¶xi ¶F(z)/ ¶xi 
Coefficients 
(Z-value) 
Independent  
Variable 
(Column- A) (Column- B) (Column- C) (Column- D) (Column- E) 
Firm Age 0.0486098*** (3.22) 0.1171 .01161679 .00200513 
0.0461297*** 
(3.67) 
SIZE 0.0225460*** (5.49) 0.4320 .00538806 .00093001 
0.0210577*** 
(8.09) 
SIZE2 -0.0000159*** 
(4.30) 
-0.3260 -3.791e-06 -6.543e-07 -0.0000142*** 
(5.72) 
DISTECH -0.0089174 
(0.70) 
-0.0118 -.00213108 -.00036784 -0.0173747 
(0.49) 
EMTECH -0.0021737 
(1.31) 
-0.0226 -.00051948 -.00008967 -0.0014154 
(0.27) 
INASSET 
0.0037849* 
(1.75) 0.1912 .00090453 .00015613 
0.0036426** 
(2.55) 
OINV 
0.0032283*** 
(3.14) 0.0772 .00077149 .00013316 
0.0027093** 
(2.04) 
EXPOINT 0.0636728*** (3.09) 0.1769 .01521654 .00262646 
0.0602249*** 
(6.25) 
PMRG 0.0127921** (2.30) 1.2505 .00305707 .00052767 
0.0120648*** 
(3.87) 
FDUM 0.5857572 
(1.21) 
0.0231 .14256104 .02465797 0.5873535 
(0.82) 
LIBDUM 3.3509366*** (3.77) 0.1624 .73797654 .12371236 
3.1924808*** 
(5.33) 
Constant -10.9466250*** (4.15)  -2.6160279 -.45154167 
-10.4132003*** 
(14.44) 
      
Sigma 7.607516        
Sigma_e     7.049186    
Sigma_u     1.201745           
Log likelihood -3001.5141     -2969.8501                    
Wald chi2(11) 60.18    214.37 
Prob > chi2      0.0000    0.0000 
Observations 1998    1998 
Number of group 277    277 
Absolute value of z-statistics in parentheses  
* Significant at 10%; ** significant at 5%; *** significant at 1%  
Note: 1. ¶Ey*/¶xi is the change in the expected value of dependent variable for cases above the limit (i.e. 
R&D intensity >0) and ¶F(z)/ ¶xi is the change in cumulative probability of being above the limit 
associated with an independent variable. 2. Marginal effects is for discrete change of dummy variable from 
0 to 1 
 
 
Firm Size: According to the vector of standardized coefficients the effect of firm size on 
R&D behaviour of Indian pharmaceutical firms stood as the second dominant factor after 
the effects of profit margin (PMRG). Not only it is the second most important factor 
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influencing R&D but it is also observed to possess non-linear effects. The firm size and 
its squared terms turn out with statistically significant positive and negative coefficients 
respectively. Apparently, firm size has a positive effect on R&D performance of firms 
but after some threshold the effect decreases with increasing levels of firm size (see 
Fugure-3). This finding of inverted U-shaped relationship between R&D and firm size 
lend support to the earlier finding of Kumar and Saqib (1996) for a sample of Indian 
manufacturing firms.  
 
Figure-3: Fitted quadratic effect of firm size on R&D intensity8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It should be noted that majority of earlier studies suggesting that firm size and 
R&D behaviour is characterized by non-linearity indicate only the shape of the 
relationship, falling short of providing any exact figure of threshold effect. In our opinion 
researchers should calculate and present the value of threshold as such a quantity may be 
of direct substantive interest for useful policy purposes and academic interest alike. For 
Indian pharmaceutical industry this information has been furnished in Table-5. The 
numerically precise estimate of the turning point after which extra size affects R&D 
                                                             
8 The graph has plotted SIZE against 0.02255*SIZE-0.000016*SIZE2.                           
 Total effect of Size with 95% value-wise confidence band  
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negatively is estimated to be Rs. 710.7 crore. Following the delta method9 the standard 
error of the turning point is computed to be 69.9. The 95% confidence interval formed on 
the assumption that the turning point is normally distributed clearly overlaps with the 
relevant range of firm size.  
 
Table-5: Analysis of the non-linear effect of firm size 
Statistics Value 
Range of Size (Rs. Crore) [.01,1983.89] 
Size+size2 has maximum in the turning point  710.6994 
Std Error of turning point (delta method)  69.9656 
95% confidence interval for the turning point (573.5693, 847.8295) 
 
 
As we know now that firm size only up to Rs. 710.7 crore has a positive impact 
on the R&D performance, it will be useful to look at the size wise distribution of the total 
sample observations10. From Table- 6 it can be seen that nearly half of the observations 
fall in the lowest size class of Rs. 0-20 crore. By the time size reach Rs. 200 crore, 90 
percent of the sample has been exhausted. There are only 25 observations that fall in the 
size class 700-above range. This finding only verify the often emphasized feature of 
Indian pharmaceutical industry as highly fragmented with more than 20, 000 firms 
competing for around Rs.19737 crore market11. The bulk of these 20, 000 firms are 
small-scale firms that are active in the industry now. Therefore, majority of Indian 
pharmaceutical firms are far below the turning point and suggests that small firm size has 
been a foremost factor responsible for keeping the R&D performance of the industry at a 
low level.  
 
Table-6:  Distribution of sample observation according to sales range 
Sales Size 
(Rs. Crores) 
Number of 
observations 
Percent Cumulative Percent 
0-20 1015 49.0 49.0 
20-50 359 17.3 66.3 
50-100 246 11.9 78.2 
100-200 238 11.5 89.7 
200-400 143 6.9 96.6 
400-700 45 2.2 98.8 
700-above 25 1.2 100.0 
Source: Authors’ computation based on RIS-DSIR database (2002) 
 
                                                             
9 Linear approximation of the nonlinear function of the turning point in the regression coefficients.  
10 The number of sample observations in the present case may not be equal to that was reported in the 
estimation as STATA had dropped some observations owing to missing values in independent variables. 
11 The production figure is for the year 1999-2000 taken from Organization of Pharmaceutical Producers of 
India (OPPI). 
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The government policy in the past had actively encouraged small-scale sector in 
the pharmaceutical industry as a part of the overall industrial development strategy of 
protecting and promoting small-scale sector to achieve a multiple of socio-economic 
objectives such as employment generation and equity, decentralized industrial 
development, tapping new sources of entrepreneurial capabilities and so on. However the 
two most important objectives that marked the government policy in the case of 
pharmaceutical industry was the objectives of self-reliance in the production of basic 
drugs and ensuring supply of cheap drugs to the poor. A number of drugs like 
Paracetamol, Parabenes, Calcium Gluconate, Benzyl Benzoate, Pyrazolones, Lanolin 
Anhydrous, Citrates, Halogenated Hydroxy Quinolines, etc have been reserved for the 
exclusive development in the small scale enterprises. The small-scale firms were kept 
outside the purview of DPCO and were exempted from the drug policy parameters. They 
were provided with substantial share of the market in the Government Health Care 
Programme.  
This policy of encouraging small-scale enterprises has significantly influenced 
the structure and development of Indian pharmaceutical industry. It led to the emergence 
of a strong small-scale sector in Indian pharmaceutical industry engaged in the 
manufacture of drugs and pharmaceuticals. Perhaps more important effects are felt on the 
production of bulk drugs and consequently on the accessibility of people to health 
security12. The government protection of small-scale sector coupled with low level of 
patent protection finally has resulted in the larger role that small firms are playing in the 
growth performance of the industry. Another upshot of this policy is the generation and 
strengthening of inter-firms linkages between small and large enterprises in the industry. 
Many large firms who formerly used to undertake all stages of drug production with their 
integrated production process started subcontracting work on several intermediate stage 
of production to various small firms to take advantage of government subsidies to the 
small-scale sector.    
As the small size firms do not have huge resources necessary for developing any 
new chemical compounds, their survival in the product patent regime without 
government support is unthinkable. Even their small size do not permit them to 
undertake adaptive innovation as reflected by the large number of firms not doing any 
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R&D at all and majority of firms who are doing is very low in proportion to their size. 
The fact that competition in pharmaceutical industry is based on technology and that 
small size firms lack resources to strengthen their technological capabilities warrant 
appropriate policy response specifically focusing on the technological needs of small 
scale sector. Just because small size firms do not have the required technological strength 
to survive in a market driven regime the country can ill-afford to see the withering of its 
small-scale sector that is so instrumental in keeping the prices of many life saving drugs 
affordable to the poor people. What the government at least could do is to strengthen the 
technology support and training for small-scale sectors. 
 
Technology Imports: None of the two measures of technology imports, viz. DISTECH 
measuring disembodied technology imports and EMTECH measuring embodied 
technology imports have come up with significant effect. The sign of both these 
variables are observed to be negative but statistically not different from zero. This 
suggests the relationship between technology imports and R&D efforts of firms is neither 
marked by complementarity nor substitution. The impact of technology imports tends to 
vary across firms and on the average does not possess any systematic effect on the 
technological efforts of importing firms. This findings is consistent with the earlier 
findings of Kumar and Saqib (1996) that the R&D activity of Indian manufacturing firms 
is neither complemented by technology import measured as technology licensing 
payments nor is substituted by it. 
 
Intangible Assets: INASSET representing the intangible assets of the firm turns up with 
a positive sign and is statistically significant at 10% level. In terms of the strength of 
relative contribution as indicated by standardized coefficients vector intangible assets of 
the firm stood as the third dominating factor. A 1-percentage increase in the intangible 
assets of the firm, on an average, bring about 0.0009 increase in R&D intensity of firms 
engaging in R&D activity keeping other variables constant. The marginal impact of 1-
percent increase in the intangible assets on the probability of firms to engage in R&D 
activity is, on an average, estimated to be about 0.00016.  The finding weakly lend 
                                                                                                                                                                                   
12 The share of small-scale sector in the production of bulk drugs has increased from 7.7 percent in 1975-
76 to 20.9 percent in 1985-86. The corresponding share of MNE affiliates has decreased from 40 percent in 
1975-76 to 18 percent in 1985-86 (see, Table-1 in Kumar and Pradhan, 2002). 
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support to our contention that firms with high brand valuation are inclined to do R&D as 
they are better placed to appropriate returns from their R&D activity.  
 
Outward Orientation: Both the measures of outward orientation, viz. OINV signifying 
serving of the foreign market through outward foreign direct investment and EXPOINT 
indicating serving of the foreign market via exports turns out with positive coefficients 
and are significant at 1% level. Obviously Indian pharmaceutical firms that are branching 
out into foreign markets whether via FDI or via exports exhibit higher probability to 
undertake R&D and invest more in R&D as a proportion of total sales. In a knowledge-
based industry like pharmaceuticals, the global competitiveness of a firm is driven by 
high technology, high skill, quality and reliability. Therefore, entry into global market 
requires a strong technological backup on the part of entrant and intense competitive 
pressure based on technological dynamism ensures that the firm is continuously 
innovative to be able to stay in the market.  
 
Profit Margins: The link between profit margins, PMRG, and R&D activity has been 
found to be positive. PMRG has come up with a positive sign and significant at 5% 
level. In particular a 1-percent increase in the profit margins of firms on an average 
increases about 0.00053 in the probability of firms to undertake R&D and about 0.0031 
in the R&D intensity of firms keeping other variables constant. The effect of this variable 
is the most significant on R&D performance as shown by the vector of standardized 
coefficients. Therefore the result suggests that internal resource generation of the firm 
significantly increases the R&D activity of Indian pharmaceutical companies.  
 
Ownership: The FDUM capturing the effect of foreign ownership on the performance of 
R&D emerges with a positive coefficient that is statistically not different from zero.  
Therefore there is no evidence to suggest that R&D behaviour of firms differs on having 
majority foreign ownership as opposed to having domestic ownership. This finding is 
particularly significant and at variant with the view that liberal FDI policy and 
strengthening of patent system will lead to a spurt in innovative activities of foreign 
firms and hence will lead to an increase in the international technology transfer to India. 
It is argued that foreign firms will introduce their new products in the country and may 
relocate their R&D units in India because of its cheap personnel costs. However the view 
that MNEs may act as an engine of R&D performance does not inspire much confidence 
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in the face of many MNEs like Ciba Geigy, Boots, Hoechst and Rhone Poulence are 
closing down their R&D units at a time when the country is moving towards a product 
patent regime. If experiences are any indication the monopoly status of MNCs may even 
lead to contraction of innovative activities as happened in the case of Patents and 
Designs Act, 1911. Given the provision of TRIPs that imports is akin to local production 
it may even result in shifting of existing R&D units in the country to the home country of 
foreign firm concerns. TRIMs, which prohibit the imposition of performance 
requirements like, export obligations, local content requirements, local manufacturing 
requirements etc. by host countries further undermine the capability of developing 
courtiers to induce foreign firms to do R&D locally13.  
 
Liberalization: The variable, LIBDUM, which capture the possible effects of 
liberalization on the R&D performance of Indian pharmaceutical firms has come out 
with a positive coefficient statistically different from zero at 1% significance level. This 
suggests that R&D performance of pharmaceutical firms has increased substantially in 
the reform period (1993-94 to 2000-01) as compared to pre-reform period (1989-90 to 
1992-93). The standardized coefficient indicate that in the post reform period R&D 
intensity of Indian pharmaceutical firms is expected to increase by 0.1624 standard 
deviations, holding all other variables constant. The marginal effects of LIMDUM on 
R&D intensity and probability to do R&D are also quite considerable. This suggests that 
liberalization of industrial, trade policies with impending product patent regime have 
made Indian pharmaceutical firms more conscious of the need to undertake R&D 
activity, and indeed they had devoted substantial resources in that direction. 
Remembering the structure of industry where majority of firms are essentially small size 
imply that the improved R&D performance in the reform period may well have come 
from the performance of a small group of large size firms. Small-scale sector due to scale 
and resource constraint are not in the position of venturing into R&D-led growth as few 
large Indian pharmaceutical firms are doing. The government incentive package often 
was of little help to small-sector as compared to large enterprises because latter are better 
                                                             
13 See UNCTAD (2001) for an illustrative list of 39 host country operational measures, pp.8-9. Historically 
both developed and developing host countries alike have used these measures as a developmental tool to 
ensure maximum benefits from foreign capital while keeping at minimum its negative impact. However, 
the use of these measures is increasingly under attack from developed countries led by the United States. 
The agreement on TRIMs in the 1994 Uruguay round GATT negotiation covered (i) local content 
requirements, (ii) export performance requirements, (iii) local manufacturing requirements, (iv) trade 
balancing requirements and (v) foreign exchange restrictions.    
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placed to obtain import permits for capital goods, intermediate inputs and raw materials 
and have preferential access in the domestic credit market. In many cases, small firms 
were ignorant of available concessions or were unable to handle the procedural and 
administrative complexity involved in the relevant office work. The fact that small-scale 
sector are instrumental in ensuring the access of poor to quality drugs calls for greater 
role of government to directly strengthening their technological capabilities so that they 
can survive in a liberalized business environment.               
 
V. Conclusions and implications  
 
Along with the implementation of macroeconomic liberalization in the country 
the nineties had witnessed significant changes in the policy regime governing Indian 
pharmaceutical industry. The progressive dilutions of DPCO, liberal FDI policy, and 
transitory measures of TRIPs have induced intense competition in the market. The above 
empirical exercise finds that this competitive pressure has worked effectively in pushing 
Indian pharmaceutical firms into R&D activity. However, it is inferred that this impact of 
liberalization is likely to be limited to be a few large and medium size firms as large 
segment of small size firms lack the huge resources that is required for product 
development. The impact of firm size is also observed to have strong non-linear impact 
on the R&D performance. Recently government has taken some initiatives like 
establishment of a Drug Development Promotion Foundation (DDPF) and a 
Pharmaceutical Research and Development Support Fund (PRDSF) in order to promote 
R&D activity in the industry. These government measures are steps in the right 
directions but also need to be target orientated towards small size firms as these firms are 
instrumental in keeping drugs prices accessible to the poor. Also at the same time we 
should promote some national champions as done by developed countries under their 
strategic trade policies. 
The R&D behaviour of Indian firms appears to be not systematically affected by 
the availability of foreign technology through licensing and imports of capital goods. 
However, the outward orientation of an enterprise is a significant determinant of in-
house R&D. Therefore government policies that encourages Indian firms to exports and 
to undertake outward direct investment are very crucial in inducing firms to focus more 
on the development of indigenous technologies. For a long time the government policy 
with respect to outward foreign direct investment has been restrictive due to the 
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insufficient foreign exchange reserves and precarious BOP position. Only joint ventures 
were promoted with minority Indian ownership and even that minor equity participation 
was required to be in the form of exports of Indian made capital goods, equipments and 
know-how. It is encouraging to note that recently these restrictions on outward direct 
investment has been liberalized. In October1992 government had issued the modified 
Guidelines for Indian Joint Ventures (JVs) and Wholly Owned Subsidiaries Abroad 
(WOSs) which provided for automatic approval for cases with equity value up to $2 
millions of which up to $ 500,000 could be in cash and rest by capitalization of Indian 
exports of machinery, equipment, know-how or other services. These procedures have 
been further liberalized in 1999 and 2002 Guidelines. These outward oriented policies 
are likely to improve the competitiveness of Indian pharmaceutical firms and hence their 
need to undertake large scale R&D activities.         
Another significant observation of the study is that the R&D behaviour of Indian 
pharmaceutical firms crucially depends on their intangible assets mainly brand valuation. 
Firms that are promoting and creating brands are found to be doing more R&D activity 
as these intangibles strengthen their power to appropriate rents from their innovative 
activity. In addition, profit margins and firm age are other two important determinants of 
R&D behaviour of Indian pharmaceutical firms. The R&D behaviour of foreign firms is 
found to be not different from domestic enterprises. 
The policy implications from the above analysis are obvious. In order to enhance 
R&D performance of Indian pharmaceutical firms the government should focus on 
removing obstacles that inhibit Indian firms participation in international markets via 
exports or via outward foreign direct investment. Recognizing the important role of firm 
size in R&D performance policy must contain special scheme for small size firms in the 
overall technology policy for the industry. Given the huge cost involved in the basic 
research, the path of collaborative research efforts between private sectors and 
government research institution appears to be an important strategic option that needs to 
be promoted seriously. Technology transfer requirements for foreign firms or other 
performance requirements that are permitted under TRIMs agreements can be utilized to 
the fullest extent to persuade foreign firms to relocate their R&D units into the country.  
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 Appendix A: Dataset and Measurements of Variables 
 
The dataset used in the present study is a sub-sample of a larger dataset, RIS-DSIR 
database, constructed from different sources at the Research and Information System for 
the Non-aligned and Other Developing Countries, as a part of the Department of 
Scientific and Industrial Research (DSIR) research project ‘A Strategic Approach to 
Strengthening the International Competitiveness in Knowledge-based Industries: Some 
Explorations into the Role of FDI Inflows, Outward Investments, and Enterprise Level 
Technological Effort in Promotion of India’s Knowledge Intensive Exports’.  The 
dataset, which covers firm-level data on various financial variables like exports, imports, 
sales, R&D, outward investments, etc. of more than 500 Indian manufacturing 
companies, has been compiled from the PROWESS database (2002), the Ministry of 
Commerce, the Ministry of Finance, and the India Investment Centre.   
 
Measurements 
 
A1. Dependent Variable 
 
R&Dit: Total R&D expenditure as a percentage of total sales of ith firm in tth year. 
 
A2. Independent Variables 
 
AGEit: The age of ith firm in number of years.  
SIZEit: Total sales of ith firm in tth year. 
SIZE2it: The squared term of the sales of ith firm in tth year.  
DISTECHit: Royalties, technical and other professional fees remitted abroad by ith firm 
as a percentage of sales in the year t.   
EMTECHit : Imports of capital goods by ith firm as a percentage of sales in tth year.  
INASSETit: Intangible asset of the ith firm as a percentage of sales in the year t. This is 
the brand valuation as given in the balance sheet of the company. 
OINVit: Defined as the stock of outward direct investment of the ith firm as a percentage 
of sales multiplied by the age of multinationality. 
EXPOINTit: Exports of ith firm as a percentage of sales in the year t. 
PMRGit: Profit before tax (PBT) as a percentage of sales. 
FDUM: Dummy variable for foreign owned firm taking value 1 for firms with 25 % or 
more foreign equity participation and 0 otherwise. 
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LIBDUM: Liberalization dummy taking 1 for reform period 1993-94 to 2000-01 and 0 
for the pre-reform period 1989-90 to 1992-93. 
